Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbook

Deep-brain stimulation principles

Explain disease-specific selection, stereotactic implantation and programming, realistic benefits and limitations, device safety, urgent complications, and the long-term multidisciplinary work required after deep-brain stimulation.

Saved on this device
!
Acute neurological or device complication

New severe headache, focal deficit, seizure, reduced consciousness, fever, wound drainage or rapidly spreading erythema after DBS can indicate haemorrhage, stroke, infection or hardware-related intracranial disease.

Action: Stop routine programming, assess ABC and neurology, contact the implanting neurosurgical and movement-disorder service urgently, and obtain cause-directed imaging and cultures without manipulating exposed hardware.

Open the sections you need. The overview is shown first.
01Core principlesThe concepts and mechanisms needed to understand the subject.

DBS is a platform rather than one treatment. The anatomical target, laterality and outcome measure depend on the diagnosed circuit disorder. Evidence for advanced Parkinson’s disease cannot be transferred automatically to essential tremor, dystonia, epilepsy, pain or psychiatric conditions, and a label alone does not establish eligibility.

The operation creates a durable care pathway. Imaging and stereotactic planning guide electrode placement, the generator supplies power, and specialist programming balances benefit against adverse effects. Patients still require medication review, rehabilitation, battery surveillance and access to a team that can interpret hardware alerts or acute illness.

Key points

  • DBS delivers adjustable electrical stimulation through stereotactically implanted intracranial leads connected to a pulse generator; it modulates a circuit and does not cure the underlying disorder.
  • Selection is diagnosis-specific. In Parkinson's disease, NICE says not to offer DBS when best medical therapy adequately controls symptoms and to consider it when advanced disease remains inadequately controlled.
  • A multidisciplinary team defines target symptoms, confirms treatment refractoriness and assesses cognition, mood, gait, levodopa response, medical fitness, support and the person’s ability to manage follow-up.
  • DBS commonly improves selected motor symptoms such as levodopa-responsive fluctuation, tremor or disease-matched dystonia; axial, cognitive and non-motor symptoms may respond poorly or worsen.
  • Implantation risks include intracranial haemorrhage, stroke, seizure and infection; later risks include erosion, lead or extension failure, battery depletion and stimulation adverse effects.
  • Programming is iterative and interacts with medicine. Abrupt symptom return demands a device and medication check, while gradual decline may reflect disease progression or loss of target benefit.
  • MRI, diathermy, surgery, cardioversion and other electromagnetic procedures require identification of the exact system and manufacturer-specific conditions.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Potential Parkinson candidate

Advanced Parkinson's disease with disabling symptoms inadequately controlled by best medical therapy may justify MDT assessment when target symptoms remain plausibly stimulation-responsive.

Disease-specific refractory disability

Severe disabling tremor or dystonia may have a DBS pathway, but selection and target differ from Parkinson's disease and require matching specialist guidance.

Poorly matched expectation

Dementia, uncontrolled psychiatric disease, severe medication-unresponsive axial dysfunction or goals centred on non-responsive symptoms can make benefit unlikely or harm unacceptable.

Postoperative emergencyRed flag

New neurological deficit, seizure, reduced consciousness, fever or wound drainage after implantation requires urgent neurosurgical assessment.

Hardware clue

Abrupt loss of benefit, intermittent stimulation, painful shocking, a palpable cable change or a controller alert suggests a power, connection or lead problem.

Red flags requiring action

  • Acute focal deficit, severe headache, seizure or depressed consciousness during or after implantation requires immediate intracranial-haemorrhage and stroke assessment.
  • Fever, wound pain, redness, erosion or discharge anywhere along the lead, extension or pulse-generator track suggests hardware infection and needs urgent specialist review.
  • Sudden loss of benefit should trigger safe device-state, battery, impedance and medication review before it is labelled disease progression.
  • New impulsivity, depression, suicidality, confusion, troublesome dysarthria or gait freezing after programming needs prompt multidisciplinary reassessment rather than repeated unsupervised amplitude increases.
03Interpreting evidenceInformation, measurements and their limitations.
Reasoning sequence

Consider the information, its meaning and its limitations before deciding what follows.

  1. 01
    Disorder-specific specialist assessment and treatment-response diary
    Why
    Confirm diagnosis, quantify disability and determine which symptoms improve with established therapy and are realistic DBS targets.
    Interpretation and limitations
    A strong levodopa response in Parkinson's disease supports potential motor benefit, but gait, speech, cognition and non-motor outcomes require separate prediction.
  2. 02
    Neuropsychological and neuropsychiatric assessment
    Why
    Describe cognition, mood, behaviour, capacity, support needs and vulnerabilities that affect consent and postoperative adjustment.
    Interpretation and limitations
    Findings inform risk and support planning; they are interpreted by the MDT rather than used as an isolated pass-fail score.
  3. 03
    Stereotactic MRI or CT planning
    Why
    Define target and trajectory while avoiding vessels, ventricles and eloquent structures.
    Interpretation and limitations
    Imaging enables safe planning but does not determine candidacy without clinical concordance and disease-specific goals.
  4. 04
    Device interrogation
    Why
    Check stimulation state, programme, battery, impedances and stored alerts when benefit changes or before relevant procedures.
    Interpretation and limitations
    An open circuit suggests disconnection or fracture; low impedance can suggest short circuit; normal readings do not exclude a clinical programming or medication problem.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked caseAdvanced Parkinson motor fluctuationsLevodopa-responsive fluctuations or tremor remain disabling despite optimised therapy and the person requests an advanced option.
  1. 1Refer to a specialist movement-disorder MDT; document best medical therapy, response profile, off-state disability, dyskinesia, gait, speech, cognition, mood, comorbidity and patient goals.
  2. 2Explain that assessment compares DBS with infusion and continuing medical options; identify target symptoms and outcomes that DBS is unlikely to improve.
  3. 3If selected, complete consent, device and imaging planning, perioperative medicine coordination and a postoperative programming plan.
  4. 4Review motor and non-motor outcome against baseline while adjusting stimulation and medication together rather than pursuing a single score.
02TroubleshootingAbrupt return of treated symptomsPreviously stable benefit is lost suddenly without a new neurological emergency.
  1. 1Confirm whether stimulation is on and whether the patient controller or recent procedure changed the programme; review battery status and medication timing.
  2. 2Contact the specialist DBS team for interrogation, impedance testing and safe programming rather than empirically escalating amplitude.
  3. 3Use radiography or other device-compatible imaging if disconnection, migration or fracture remains likely; reserve revision for a demonstrated correctable fault.
03Urgent complicationDeficit, infection or erosionNew focal neurology, seizure, severe headache, fever, wound breakdown or visible hardware occurs.
  1. 1Treat neurological deterioration as possible haemorrhage or stroke and obtain emergency imaging with neurosurgical involvement.
  2. 2For suspected infection, obtain clinically appropriate cultures and specialist assessment; do not swab or manipulate deep exposed components casually.
  3. 3Coordinate antimicrobial and partial or complete hardware management through neurosurgery and infection specialists because anatomy, organism and depth change the plan.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
  • At each DBS review, measure the patient’s predefined target symptoms in relevant medication and stimulation states and record speech, gait, falls, cognition, mood and daily function.
  • Track battery longevity, charging performance, impedances, hardware discomfort, scalp and chest skin integrity and upcoming procedures that may interact with the device.
  • Reconcile antiparkinsonian or other disorder-specific medicines after programming; abrupt withdrawal or excessive reduction can cause serious deterioration.
  • Provide a device card, manufacturer-specific emergency information and a route to the implanting service; revisit goals as the underlying disease progresses.
06Special situationsVariants, exceptions and circumstances that change the usual approach.

Target the symptom

A diagnostic label starts selection, but the MDT must identify the disabling symptom that stimulation can plausibly modify.

Programming is treatment

Electrode implantation alone does not complete DBS; careful parameter and medicine adjustment creates the therapeutic effect.

Hardware spans compartments

Infection may involve scalp, connector, extension or chest generator, so the visible site does not define the whole extent.

Progression changes balance

Later cognitive, gait or speech decline may narrow benefit even while stimulation continues to control the original motor target.

07Common pitfallsFrequent interpretation and management errors.
  1. 01

    Treating DBS as curative creates unrealistic expectations and obscures progression of non-responsive symptoms.

  2. 02

    Using Parkinson's disease evidence to select every tremor or dystonia patient ignores different targets, phenotypes and outcome evidence.

  3. 03

    Calling abrupt symptom return ordinary progression misses battery depletion, accidental switch-off, programme change or hardware failure.

  4. 04

    Permitting MRI or diathermy from the generic label DBS without exact device conditions risks heating, tissue injury or device malfunction.

Practice

Two practice questions

Question 1 of 20 correct
NeurosurgeryOriginal SBA

Parkinson disease selection

A person with advanced Parkinson's disease has disabling levodopa-responsive motor fluctuations despite optimised medical therapy and asks about deep-brain stimulation. What is the correct next principle?

Sources and review status4 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 13 Sept 2026; clinical approval remains outstanding.

  • NICE NG71 Parkinson's disease in adultsPublished 19 July 2017; current recommendations body read 13 September 2026. Scope; advanced therapies and deep-brain-stimulation recommendations; information, multidisciplinary care and non-motor symptom sections. Supports: Do not offer DBS when symptoms are adequately controlled by best medical therapy; consider it for advanced Parkinson's disease inadequately controlled by best medical therapy. Limits: Adults with Parkinson's disease in UK NHS care; it does not define DBS eligibility for essential tremor, dystonia, epilepsy or psychiatric disease. Chapter-specific use: deep-brain-stimulation-principles.
  • NICE HTG7 deep brain stimulation for Parkinson's diseaseOriginally published 26 November 2003; current migrated HealthTech guidance body read 13 September 2026. Recommendations 1.1 to 1.3 and procedure safety summary. Supports: Governance, consent, audit and multidisciplinary selection for disease refractory to best medical treatment. Limits: Interventional-procedure evidence for Parkinson's disease; current clinical selection should be read with NG71. Chapter-specific use: deep-brain-stimulation-principles.
  • Identification and management of DBS urgencies and emergenciesParkinsonism & Related Disorders review published 2010; relevant full-text sections read 13 September 2026. Hardware malfunction; accidental on/off; symptom rebound; Table 2 postoperative urgency and emergency management. Supports: Abrupt loss of established benefit warrants checking whether the device is on, using the patient remote/controller, and a DBS hardware work-up including battery and impedance checks; imaging follows when a structural fault remains possible. Limits: Professional review centred on movement-disorder DBS and older Medtronic-era systems; exact controller functions, alert thresholds, programming and imaging conditions remain manufacturer- and model-specific. Chapter-specific use: deep-brain-stimulation-principles.
  • NICE HTG122 DBS for tremor and dystonia excluding Parkinson's diseasePublished 23 August 2006; current migrated HealthTech body read 13 September 2026. Indications 2.1.1 to 2.1.5; procedure; efficacy and safety sections. Supports: Disease-specific separation of severe disabling refractory tremor and dystonia from Parkinson's disease, and recognised procedural risks. Limits: Excludes Parkinsonian tremor and dystonia; older interventional guidance does not substitute for contemporary disorder-specific MDT assessment. Chapter-specific use: deep-brain-stimulation-principles.
Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom